About Immunocure
Immunocure is a company based in Brooklyn (United States) founded in 2019 by BDL Nageswara Rao, Ravi Kumar Muttineni, and K K Raj. Immunocure has raised $97.88 thousand across 1 funding round from investors including Murali Chand Ginjupalli. Immunocure offers products and services including AxDrug Platform, Synthesis Services, Hit Identification, and Lead Optimization. Immunocure operates in a competitive market with competitors including Biogen, Biological E, Vir Biotechnology, ADMA Biologics and Kymeratx, among others.
- Headquarter Brooklyn, United States
- Founders BDL Nageswara Rao, Ravi Kumar Muttineni, K K Raj
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunocure Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$97.88 K (USD)
in 1 rounds
-
Latest Funding Round
$97.88 K (USD), Angel Round
May 23, 2019
-
Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immunocure
Immunocure offers a comprehensive portfolio of products and services, including AxDrug Platform, Synthesis Services, Hit Identification, and Lead Optimization.
AI platform for virtual screening and lead generation in drug discovery
Services for optimizing and synthesizing small molecules and peptides
Process for virtual screening of databases to identify potential hits
AI-assisted optimization of lead molecules for drug candidacy
Funding Insights of Immunocure
Immunocure has successfully raised a total of $97.88K through 1 strategic funding round. The most recent funding activity was a Angel Round of $97.88 thousand completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immunocure
Immunocure has secured backing from 1 investor, including angel investors. Prominent investors backing the company include Murali Chand Ginjupalli.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
MC
Murali Chand Ginjupalli |
-
|
Locked | Locked | Locked |
Investor details for Immunocure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunocure
Investment portfolio details for Immunocure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immunocure
Detailed financials for Immunocure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunocure Comparisons
Peer comparison for Immunocure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immunocure
Immunocure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Biological E, Vir Biotechnology, ADMA Biologics and Kymeratx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Vaccines and therapeutics for multiple diseases are developed and marketed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of infectious diseases
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases are developed using cell-free protein synthesis.
|
Detailed competitors of Immunocure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunocure
Complete news archive for Immunocure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunocure
Immunocure was founded in 2019.
Immunocure is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.
BDL Nageswara Rao is the current CEO of Immunocure. They have also founded this company.
Immunocure is a funded company, having raised a total of $97.88K across 1 funding round to date.
Immunocure was founded in 2019 and is based in Brooklyn, United States. Drug discovery contract research organization services are delivered, with a focus on computational chemistry enhanced by AI, machine learning, and deep learning tools. Lead compounds are developed for clients, alongside computational modeling for drug development. Additional services encompass AI-based cosmetic design and agrochemical discovery, supporting sectors like pharmaceuticals and agriculture.
Immunocure's top competitors include ADMA Biologics, Vaxcyte and BioNTech.
Immunocure offers AxDrug Platform, Synthesis Services, Hit Identification, and Lead Optimization.
Immunocure has 1 investor. Key investors include Murali Chand Ginjupalli.